Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aromasin randomized trial with or without Sutent as neoadjuvant therapy for postmenopausal women with breast cancer
ISRCTN11277575Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Mar 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of exemestane and sunitinib in breast cancer (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Ki67 response to therapy. Started Mar 2008; status: terminated.
02
Drugs
exemestanesunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN11277575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11277575.